Blockade of the forward Na+/Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+‐mediated cell death. (17th June 2019)
- Record Type:
- Journal Article
- Title:
- Blockade of the forward Na+/Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+‐mediated cell death. (17th June 2019)
- Main Title:
- Blockade of the forward Na+/Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+‐mediated cell death
- Authors:
- Hu, Hui‐Jie
Wang, Shan‐Shan
Wang, Yan‐Xia
Liu, Yan
Feng, Xue‐Mei
Shen, Ying
Zhu, Liang
Chen, Hong‐Zhuan
Song, Mingke - Abstract:
- Abstract : Background and Purpose: The Na + /Ca 2+ exchanger (NCX) working in either forward or reverse mode participates in maintaining intracellular Ca 2+ ([Ca 2+ ]i ) homeostasis, which is essential for determining cell fate. Previously, numerous blockers targeting reverse or forward NCX have been developed and studied in ischaemic tissue injury but barely examined in glioblastoma for the purpose of anti‐tumour therapy. We assessed the effect of NCX blockers on glioblastoma growth and whether NCX can become a therapeutic target. Experimental Approach: Patch‐clamp recording, Ca 2+ imaging, flow cytometry, and Western blot were used to study the effects of specific and non‐specific NCX blockers on cultured glioblastoma cells. In vivo bioluminescent imaging was used to measure effects on grafted glioblastoma. Key Results: Selectively blocking the reverse NCX with SEA0400, SN‐6, and YM‐244769 did not affect tumour cell viability. Blocking the forward NCX with bepridil, CB‐DMB, or KB‐R7943 elevated [Ca 2+ ]i and killed glioblastoma cells. Bepridil and CB‐DMB caused Ca 2+ ‐dependent cell cycle arrest together with apoptosis, which were all attenuated by a Ca 2+ chelator BAPTA‐AM. Systemic administration of bepridil inhibited growth of brain‐grafted glioblastoma. Bepridil did not appear to have a cytotoxic effect on human astrocytes, which have higher functional expression of NCX than glioblastoma cells. Conclusions and Implications: Low expression of the NCX makes glioblastomaAbstract : Background and Purpose: The Na + /Ca 2+ exchanger (NCX) working in either forward or reverse mode participates in maintaining intracellular Ca 2+ ([Ca 2+ ]i ) homeostasis, which is essential for determining cell fate. Previously, numerous blockers targeting reverse or forward NCX have been developed and studied in ischaemic tissue injury but barely examined in glioblastoma for the purpose of anti‐tumour therapy. We assessed the effect of NCX blockers on glioblastoma growth and whether NCX can become a therapeutic target. Experimental Approach: Patch‐clamp recording, Ca 2+ imaging, flow cytometry, and Western blot were used to study the effects of specific and non‐specific NCX blockers on cultured glioblastoma cells. In vivo bioluminescent imaging was used to measure effects on grafted glioblastoma. Key Results: Selectively blocking the reverse NCX with SEA0400, SN‐6, and YM‐244769 did not affect tumour cell viability. Blocking the forward NCX with bepridil, CB‐DMB, or KB‐R7943 elevated [Ca 2+ ]i and killed glioblastoma cells. Bepridil and CB‐DMB caused Ca 2+ ‐dependent cell cycle arrest together with apoptosis, which were all attenuated by a Ca 2+ chelator BAPTA‐AM. Systemic administration of bepridil inhibited growth of brain‐grafted glioblastoma. Bepridil did not appear to have a cytotoxic effect on human astrocytes, which have higher functional expression of NCX than glioblastoma cells. Conclusions and Implications: Low expression of the NCX makes glioblastoma cells sensitive to disturbance of [Ca 2+ ]i . Interventions designed to block the forward NCX can cause Ca 2+ ‐mediated injury to glioblastoma thus having therapeutic potential. Bepridil could be a lead compound for developing new anti‐tumour drugs. … (more)
- Is Part Of:
- British journal of pharmacology. Volume 176:Number 15(2019)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 176:Number 15(2019)
- Issue Display:
- Volume 176, Issue 15 (2019)
- Year:
- 2019
- Volume:
- 176
- Issue:
- 15
- Issue Sort Value:
- 2019-0176-0015-0000
- Page Start:
- 2691
- Page End:
- 2707
- Publication Date:
- 2019-06-17
- Subjects:
- Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.14692 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 14241.xml